| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15130599 | IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| PMID:16962624 | IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.000001 M | 0.00000003 - 0.000001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:18626888 | IVTH | 0.00000005 - 0.0001 M | 0.000004 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000005 - 0.0001 M | 0.000004 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:19733639 | IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decreased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.00001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.00000001 - 0.00001 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:20087668 | IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.0001 M | 0.0000003 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:20708073 | IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.00003 M | 0.0000001 - 0.00003 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:23616146 | IVTH | 0.000001 - 0.01 mmol/L | 0.0001 - 0.1 mmol/L | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.01 mmol/L | 0.0001 - 0.1 mmol/L | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:24486430 | IVTH | 0.000001 - 0.000003 M | 0.000001 - 0.000003 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.000003 M | 0.000001 - 0.000003 M | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| PMID:25324206 | IVTH | 0.00003 M | 0.00003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00003 M | 0.00003 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000003 M | 0.000003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000003 M | - | No significant effects observed | - | |
| IVTH | 0.000001 M | 0.000001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| PMID:26914364 | IVR | 0.01 mg/kg/day | - | No significant effects observed | - |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Nipple retention | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.